Opportunity opens for integrated NGS and molecular biology platforms
A new consultation for automated PCR, extraction and NGS systems highlights how public buyers are reshaping laboratory workflows and long-term DNA testing capacity.
A new consultation for automated PCR, extraction and NGS systems highlights how public buyers are reshaping laboratory workflows and long-term DNA testing capacity.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
In November 2025, public buyer Resah opened a consultation to source a full suite of molecular biology and next-generation sequencing (NGS) solutions, from automated PCR systems to library preparation kits. The planned purchase points to sustained investment in DNA testing and pathogen detection capacity across Europe’s public laboratories.
The consultation on molecular biology and NGS solutions sets out Resah’s intention to identify suppliers for a broad range of technologies and consumables. According to the notice, the scope includes:
These elements span the core molecular workflow, from nucleic acid extraction through PCR to sequencing, and the reference to the term multiple throughput levels points to a need for both low- and high-volume options.
By grouping automated PCR instruments, extraction platforms and NGS solutions into a single exercise, Resah appears to be looking at the laboratory process as a whole, rather than as a set of isolated purchases. That mirrors a wider European shift towards integrated molecular testing pipelines.
In September 2025, CHU de Toulouse sought molecular biology reagents and consumables together with nucleic acid extractors, qPCR instruments and library preparation systems, signalling a similar desire to align reagents and hardware. Earlier, in June 2025, Centre Hospitalier Universitaire de Nîmes launched a framework agreement for molecular biology consumables ranging from oligonucleotides to PCR and quantification kits.
For cancer centres, the need for coherent molecular platforms is explicit. In September 2025, UNICANCER ACHATS went to market for the implementation, delivery, installation, commissioning and maintenance of molecular biology equipment and consumables for Cancer Control Centres. In October 2025, A.O. Sant'Andrea in Rome similarly sought machine-reagent systems and consumables for nucleic acid sequencing and molecular biology investigations across several technologies and platforms.
Resah’s consultation focuses on hardware and wet-lab components, but it lands in a market where public buyers increasingly seek complete NGS ecosystems, bundling instruments with reagents, maintenance, training and data analysis.
In August 2025, 69 UniHA issued a contract notice for second-generation NGS sequencers that explicitly included reagents, consumables, maintenance services and user training. A near-identical specification appeared in September 2025 from UNIHA-GCS, underlining how consortia now frame sequencers as long-term service platforms rather than one-off purchases.
Elsewhere, the order from Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy in September 2025 bundled next-generation sequencers of different throughputs with a pipetting station, assembly, installation, commissioning and training. The emphasis again is on fully operational diagnostic capability, not just the core instrument.
A number of buyers now go further and procure bioinformatics alongside reagents. In July 2025, Vilniaus universiteto ligoninė Santaros klinikos sought reagents, disposables and bioinformatics analysis for cytogenomics, epigenomics and NGS, including DNA and RNA library preparation kits and sequencing management. In August 2025, Centre Hospitalier Universitaire de Clermont Ferrand combined NGS sequencing reagents with associated bioinformatics services for its genetics laboratory.
Some institutions choose not to run NGS in-house at all. In November 2025, Rīgas Stradiņa universitāte tendered for NGS outsourcing services that range from 16S rRNA sequencing to whole genomes, transcriptomes and methylation microarrays. In September 2025, INRAE focused on high-throughput DNA and RNA sequencing services, including genome, methylation and gene-expression analyses, with secure data delivery.
Against that backdrop, Resah’s focus on automated PCR, extraction systems, sequencing solutions and library preparation kits places it squarely within a trend towards end-to-end molecular workflows. The brief description does not spell out requirements for maintenance or data management, but comparable procurements suggest that suppliers may be judged on their ability to support complete testing pathways.
While Resah’s notice does not state specific clinical indications, the surrounding wave of public-sector tenders shows where demand for molecular and NGS capacity is strongest: oncology, infectious disease and population screening.
On the oncology side, several centres are investing in NGS to refine diagnosis and treatment. In July 2025, Centrum Onkologii Ziemi Lubelskiej sought a next-generation sequencing system and associated devices for its Clinical Genetics Centre to support specialised diagnostics and treatment for oncological patients. A project published in July 2025 at SPITALUL CLINIC JUDETEAN DE URGENTA SF. APOSTOL ANDREI in Constanta aimed to enhance oncological treatment accessibility through advanced genetic equipment for its pathology and medical genetics laboratories.
In October 2025, ASST SPEDALI CIVILI DI BRESCIA moved to procure NGS analytical systems, sequencers, reagents and bioinformatics software for genomic profiling and molecular characterisation in oncology and hereditary diseases. In September 2025, Wielkopolskie Centrum Onkologii focused on reagents and consumables for molecular biology, including NGS sequencing reagents and DNA library preparation.
Also in November 2025, Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii sought laboratory materials, disposables and software licences for genetic variant analysis and classification, including reagents for various cancer diagnostics and molecular biology applications. Such procurements show how oncology services rely on tightly linked wet-lab and informatics capabilities.
Infectious disease and screening programmes form the other major driver. In June 2025, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Szczecinie combined reagents for detecting HIV, HCV and HBV RNA with the lease of automated testing devices and integration into its existing IT system. In July 2025, the public health laboratory of Land Baden-Württemberg sought a fully automated real-time PCR system for HIV/AIDS and STI diagnostics, capable of processing more than 250 samples in eight hours.
Screening workflows are also prominent. In September 2025, Healthcare Public Procurement (HeCaPP) called for a molecular biology automation system linked to HPV screening kits, underlining how automation underpins large-scale preventive programmes. In October 2025, Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji combined the purchase and successive delivery of reagents with the lease of devices for molecular biology, real-time PCR, genetic tests and automated diagnostics.
Resah’s consultation does not confine itself to a single disease area, but by spanning PCR, extraction and sequencing it could enable participating laboratories to support both oncology and infectious disease testing on shared platforms. That flexibility is a recurring theme across current public-sector investments.
For suppliers of molecular biology and NGS technologies, the consultation from Resah is another signal that public buyers want integrated, automated solutions that can sustain high-quality DNA testing and pathogen detection. The focus on automated PCR systems, nucleic acid extraction and multi-throughput library preparation points to expectations around scalability and standardisation.
Recent notices show that competition now turns on more than instrument performance. Projects such as those at Szczecin’s blood centre, which require analyser leasing and IT integration, or Bydgoszcz’s oncology centre, which emphasises installation and training, suggest that implementation support, connectivity and reagent continuity are becoming decisive factors. Suppliers engaging with Resah are likely to be assessed on how well they can underpin the whole lifecycle of molecular testing.
The summary of Resah’s consultation does not disclose information on contract structure, expected volumes or timelines. Those details will matter for both large manufacturers and smaller specialist providers of sequencing kits and library preparation reagents. As more documentation emerges, it will become clearer how far the buyer intends to consolidate demand and how open the competition will be to a mix of platforms and service models.
For now, the consultation confirms that investment in molecular biology and NGS infrastructure remains a priority in November 2025. With hospitals, research institutes and public health agencies across Europe procuring everything from high-throughput sequencers to outsourced NGS services, the market is crowded and technically demanding.
How Resah shapes its final specifications—particularly around automation levels, throughput tiers and support services—will show whether it follows the dominant model of fully integrated ecosystems or leaves more room for modular offerings. Either way, the exercise will be closely watched by suppliers seeking to position their platforms at the centre of public-sector DNA testing and pathogen detection.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.